Trade-Ideas: Endo International (ENDP) Is Today's Unusual Social Activity Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Endo International ( ENDP) as an unusual social activity candidate. In addition to specific proprietary factors, Trade-Ideas identified Endo International as such a stock due to the following factors:

  • ENDP has 13x the normal benchmarked social activity for this time of the day compared to its average of 4.68 mentions/day.
  • ENDP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $167.4 million.

Identifying stocks with 'Unusual Social Activity' tends to be a valuable process for traders looking to capitalize on the 'talk of the town' stocks that are basking in far more attention from the StockTwits financial community than normal. Good press? Bad press? It ultimately doesn't matter if it's good or bad if you know how to trade around the sentiment. Certain hedge funds use such data for their proprietary algorithms and it is not uncommon to see shared social sentiment play itself out in a stock's price trend.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ENDP with the Ticky from Trade-Ideas. See the FREE profile for ENDP NOW at Trade-Ideas

More details on ENDP:

Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Currently there are 11 analysts that rate Endo International a buy, no analysts rate it a sell, and 4 rate it a hold.

If you liked this article you might like

Illumina Shares Spike on Strong Earnings, Upside Still Remains: Biotech Movers

Geron Shares Take a Dive After J&J Unit-Led Trial Falters; Endo Closes Higher: Biotech Movers

Top Ranking Democrat McCaskill Expands Probe into Opioid Crisis

Canadian Pharma Goes Before FDA Panel Wednesday on Tamper Resistant Opioid

3 Biotech Stocks on Readers' Minds